PYXIS ONCOLOGY, INC.

Pyxis Oncology (PYXS) is a clinical-stage biotechnology company focused on developing novel oncology therapies. As a small-cap firm (market capitalisation roughly $222.02M), the company’s value is closely tied to the progress of its development pipeline, clinical trial results and ability to secure additional funding or partnerships. Investors should expect significant volatility: clinical readouts can move the stock sharply in either direction and the company may require further capital raises that dilute existing shareholders. The stock may appeal to investors seeking exposure to early-stage biotech innovation, but it is higher risk than established pharmaceutical stocks. This summary is for general educational purposes only and not personalised investment advice. Past performance is not indicative of future returns, and investors should assess their risk tolerance, investment horizon and seek professional guidance before investing in speculative biotech equities.